Clinical Trial Update: Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update exploring circulating tumor DNA (ctDNA) metrics in posttransplant lymphoproliferative disorder (PTLD).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-transplant Lymphoproliferative Disorder

Snippet

Sponsor: Jennifer Amengual | Conditions: Lymphoma, Lymphoma, B-Cell | Phase 2 | Status: RECRUITING